Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01928537
Title Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Onconova Therapeutics, Inc.
Indications

bone marrow cancer

Therapies

Rigosertib Sodium

Age Groups: adult
Covered Countries USA


No variant requirements are available.